{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:37:16Z","timestamp":1761514636559,"version":"3.40.5"},"reference-count":73,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2021,1,27]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Refractory epilepsy is a type of epilepsy involving seizures uncontrolled by first or second-\nline anticonvulsant drugs at a regular therapeutic dose. Despite considerable growth in epileptic\npharmacotherapy, one-third of the patients are resistant to current therapies. In this, the mechanisms\nresponsible for resistant epilepsy are either increased expulsion of antiepileptic drugs (AEDs)\nby multidrug resistance (MDR) transporters from the epileptogenic tissue or reduced sensitivity\nof drug in epileptogenic brain tissue. The difficulty to treat refractory epilepsy is because of drug resistance\ndue to cellular drug efflux, use of drug monotherapy, and subtherapeutic dose administration.\nIncreased expression of Pgp is also responsible for resistance epilepsy or refractory epilepsy.\nIncreased glutamate expression via inhibition of cyclooxygenase-II (COX-II) enzyme also upregulate\nP-glycoprotein (Pgp) expression and augment instance of recurrent seizures. Peripheral and\ncentral inhibition of Pgp is a powerful tool to control this drug resistant epilepsy. Drug resistance\nprimarily involves multidrug resistance (MDR1) gene responsible for encoding P-glycoprotein (Pg-\nP1 or MDR1). Currently, there is no drug under clinical practice which inhibits MDR1. The present\nreview cites some drugs like Calcium Channel Blockers (CCBs), COX-II inhibitors, and glutamate\nreceptors antagonists that inhibit P-gp. The exploitation of these targets may emerge as a beneficial\napproach for patients with drug-resistant epilepsy. The present review further highlights the\nmechanistic role of Pgp in drug-resistant epilepsy, glutamate role in drug efflux, and management\napproach.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527319999200819093109","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T18:29:17Z","timestamp":1598466557000},"page":"741-749","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Novel Approach to Refractory Epilepsy by Targeting Pgp Peripherally and Centrally: Therapeutic Targets and Future Perspectives"],"prefix":"10.2174","volume":"19","author":[{"given":"Urvashi","family":"Langeh","sequence":"first","affiliation":[{"name":"Research Scholar, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab-142001, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Chawla","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab-142001, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghanshyam Das","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab-142001, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-6632","authenticated-orcid":true,"given":"Shamsher","family":"Singh","sequence":"additional","affiliation":[{"name":"Neuroscience Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab-142001, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"831","volume":"Vol. II","author":"Adams F.","year":"1849","unstructured":"Adams F.;  The genuine works of Hippocrates 1849,Vol. II,831-858","journal-title":"The genuine works of Hippocrates"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tins.2012.11.008","volume":"36","author":"Devinsky O.","year":"2013","unstructured":"Devinsky O.; Vezzani A.; Najjar S.; De Lanerolle N.C.; Rogawski M.A.; Glia and epilepsy: excitability and inflammation. Trends Neurosci 2013,36(3),174-184","journal-title":"Trends Neurosci"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","volume":"393","author":"Thijs R.D.","year":"2019","unstructured":"Thijs R.D.; Surges R.; O\u2019Brien T.J.; Sander J.W.; Epilepsy in adults. Lancet 2019,393(10172),689-701","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","volume":"37","author":"Laxer K.D.","year":"2014","unstructured":"Laxer K.D.; Trinka E.; Hirsch L.J.; Cendes F.; Langfitt J.; Delanty N.; Resnick T.; Benbadis S.R.; The consequences of refractory epilepsy and its treatment. Epilepsy Behav 2014,37,59-70","journal-title":"Epilepsy Behav"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/epi.16097","volume":"60","author":"Hamberger M.J.","year":"2019","unstructured":"Hamberger M.J.; Schevon C.A.; Seidel W.T.; McKhann G.M.; Morrison C.; Cortical naming sites and increasing age in adults with refractory epilepsy: More might be less. Epilepsia 2019,60(8),1619-1626","journal-title":"Epilepsia"},{"key":"ref=6","first-page":"248","volume":"17","author":"Zang K","year":"2018","unstructured":"Zang K; Zhang Y; Hu J; Wang Y.; The large conductance calcium-and voltage-activated potassium channel (bk) and epilepsy. (CNS  2018,17(4),248-54","journal-title":"(CNS"},{"key":"ref=7","first-page":"272","volume":"17","author":"Zhu Y","year":"2018","unstructured":"Zhu Y; Zhang S; Feng Y; Xiao Q; Cheng J; Tao J.; The Yin and Yang of BK channels in epilepsy. (CNS  2018,17(4),272-9","journal-title":"(CNS"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.4103\/0972-2327.128643","volume":"17","author":"Santhosh N.S.","year":"2014","unstructured":"Santhosh N.S.; Sinha S.; Satishchandra P.; Epilepsy: Indian perspective. Ann Indian Acad Neurol 2014,17(Suppl. 1),S3-S11","journal-title":"Ann Indian Acad Neurol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.2147\/NDT.S84852","volume":"12","author":"Dalic L.","year":"2016","unstructured":"Dalic L.; Cook M.J.; Managing drug-resistant epilepsy: challenges and solutions. Neuropsychiatr Dis Treat 2016,12,2605-2616","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"107605","DOI":"10.1016\/j.neuropharm.2019.04.011","volume":"167","author":"L\u00f6scher W.","year":"2020","unstructured":"L\u00f6scher W.; The holy grail of epilepsy prevention: Preclinical approaches to antiepileptogenic treatments. Neuropharmacology 2020,167,107605-107619","journal-title":"Neuropharmacology"},{"key":"ref=11","first-page":"1879","author":"Binder D.K.","year":"2008","unstructured":"Binder D.K.; Schramm J.;  Epilepsy: A Comprehensive Textbook 2008,1879-1889","journal-title":"Epilepsy: A Comprehensive Textbook"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fnhum.2018.00092","volume":"12","author":"Alba-Ferrara L.","year":"2018","unstructured":"Alba-Ferrara L.; Kochen S.; Hausmann M.; Emotional Prosody Processing in Epilepsy: Some Insights on Brain Reorganization. Front Hum Neurosci 2018,12,92","journal-title":"Front Hum Neurosci"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2741\/4295","volume":"19","author":"Castaneda-Arellano R.","year":"2014","unstructured":"Castaneda-Arellano R.; Beas-Zarate C.; Feria-Velasco A.I.; Bitar-Alatorre E.W.; Rivera-Cervantes M.C.; From neurogenesis to neuroprotection in the epilepsy: signalling by erythropoietin. Front Biosci 2014,19,1445-1455","journal-title":"Front Biosci"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1474-4422(10)70310-0","volume":"10","author":"Pitk\u00e4nen A.","year":"2011","unstructured":"Pitk\u00e4nen A.; Lukasiuk K.; Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011,10(2),173-186","journal-title":"Lancet Neurol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2016.11.022","volume":"44","author":"Golyala A.","year":"2017","unstructured":"Golyala A.; Kwan P.; Drug development for refractory epilepsy: The past 25 years and beyond. Seizure 2017,44,147-156","journal-title":"Seizure"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2174\/1871527318666191119125515","volume":"18","author":"Dong S","year":"2019","unstructured":"Dong S; Liu Y; Xu J; Hu Y; Huang L; Wang Z.; Synthesis and Evaluation of N-substituted (Z)-5-(benzo [d][1, 3] dioxol-5-ylmethylene)-2-thioxothiazolidin-4-one Derivatives and 5-substitutedthioxothiazolidindione Derivatives as Potent Anticonvulsant Agents CNS  2019,18(10),798-807","journal-title":"CNS"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2007.00992.x","volume":"48","author":"French J.A.","year":"2007","unstructured":"French J.A.; Refractory epilepsy: clinical overview. Epilepsia 2007,48(Suppl. 1),3-7","journal-title":"Epilepsia"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14581\/jer.15001","volume":"5","author":"Sharma A.K.","year":"2015","unstructured":"Sharma A.K.; Rani E.; Waheed A.; Rajput S.K.; Pharmacoresistant epilepsy: a current update on non-conventional pharmacological and non-pharmacological interventions. J Epilepsy Res 2015,5(1),1-8","journal-title":"J Epilepsy Res"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1535-7511.2006.00137.x","volume":"6","author":"French J.A.","year":"2006","unstructured":"French J.A.; Refractory epilepsy: one size does not fit all. Epilepsy Curr 2006,6(6),177-180","journal-title":"Epilepsy Curr"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"a022848","DOI":"10.1101\/cshperspect.a022848","volume":"5","author":"Sirven J.I.","year":"2015","unstructured":"Sirven J.I.; Epilepsy: a spectrum disorder. Cold Spring Harb Perspect Med 2015,5(9),a022848","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"Fisher R.S.","year":"2014","unstructured":"Fisher R.S.; Acevedo C.; Arzimanoglou A.; Bogacz A.; Cross J.H.; Elger C.E.; Engel J.; Forsgren L.; French J.A.; Glynn M.; Hesdorffer D.C.; Lee B.I.; Mathern G.W.; Mosh\u00e9 S.L.; Perucca E.; Scheffer I.E.; Tomson T.; Watanabe M.; Wiebe S.; ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014,55(4),475-482","journal-title":"Epilepsia"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.4103\/0972-2327.128644","volume":"17","author":"Engel J.","year":"2014","unstructured":"Engel J.; Approaches to refractory epilepsy. Ann Indian Acad Neurol 2014,17(Suppl. 1),S12-S17","journal-title":"Ann Indian Acad Neurol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3329\/nimcj.v5i2.23137","volume":"5","author":"Islam F.","year":"2014","unstructured":"Islam F.; Ahmed S.; Yasmeen B.N.; Begum N.; Sharmin S.; Hilaly L.; Hyder R.T.; Recent advances in the management of epilepsy. North Int Med Coll J 2014,5(2),353-356","journal-title":"North Int Med Coll J"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/awh726","volume":"129","author":"Sillanp\u00e4\u00e4 M.","year":"2006","unstructured":"Sillanp\u00e4\u00e4 M.; Schmidt D.; Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006,129(Pt 3),617-624","journal-title":"Brain"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5698\/1535-7597-14.3.136","volume":"14","author":"Gidal B.E.","year":"2014","unstructured":"Gidal B.E.; P-glycoprotein expression and pharmacoresistant epilepsy: cause or consequence? Epilepsy Curr 2014,14(3),136-138","journal-title":"Epilepsy Curr"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.yebeh.2019.04.004","volume":"97","author":"Catchpool M.","year":"2019","unstructured":"Catchpool M.; Dalziel K.; Mahardya R.T.K.; Harvey A.S.; Cost-effectiveness of epileptic surgery compared with medical treatment in children with drug-resistant epilepsy. Epilepsy Behav 2019,97,253-259","journal-title":"Epilepsy Behav"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1528-1167.2005.54904.x","volume":"46","author":"Schmidt D.","year":"2005","unstructured":"Schmidt D.; L\u00f6scher W.; Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia 2005,46(6),858-877","journal-title":"Epilepsia"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/ana.25554","volume":"86","author":"Xu C.","year":"2019","unstructured":"Xu C.; Wang Y.; Zhang S.; Nao J.; Liu Y.; Wang Y.; Ding F.; Zhong K.; Chen L.; Ying X.; Wang S.; Zhou Y.; Duan S.; Chen Z.; Subicular pyramidal neurons gate drug resistance in temporal lobe epilepsy. Ann Neurol 2019,86(4),626-640","journal-title":"Ann Neurol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/ana.10473","volume":"53","author":"Remy S.","year":"2003","unstructured":"Remy S.; Gabriel S.; Urban B.W.; Dietrich D.; Lehmann T.N.; Elger C.E.; Heinemann U.; Beck H.; A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol 2003,53(4),469-479","journal-title":"Ann Neurol"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-409X(98)00085-4","volume":"36","author":"Schinkel A.H.","year":"1999","unstructured":"Schinkel A.H.; P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999,36(2-3),179-194","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s41598-018-19325-x","volume":"8","author":"Nanayakkara A.K.","year":"2018","unstructured":"Nanayakkara A.K.; Follit C.A.; Chen G.; Williams N.S.; Vogel P.D.; Wise J.G.; Targeted inhibitors of P-glycoprotein increase chemotherapeutic-induced mortality of multidrug resistant tumor cells. Sci Rep 2018,8(1),967","journal-title":"Sci Rep"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1046\/j.1528-1157.2001.12301.x","volume":"42","author":"Dombrowski S.M.","year":"2001","unstructured":"Dombrowski S.M.; Desai S.Y.; Marroni M.; Cucullo L.; Goodrich K.; Bingaman W.; Mayberg M.R.; Bengez L.; Janigro D.; Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001,42(12),1501-1506","journal-title":"Epilepsia"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/sj.tpj.6500413","volume":"7","author":"Leschziner G.D.","year":"2007","unstructured":"Leschziner G.D.; Andrew T.; Pirmohamed M.; Johnson M.R.; ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J 2007,7(3),154-179","journal-title":"Pharmacogenomics J"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1528-1167.2012.03704.x","volume":"53","author":"Feldmann M.","year":"2012","unstructured":"Feldmann M.; Koepp M.; P-glycoprotein imaging in temporal lobe epilepsy: in vivo PET experiments with the Pgp substrate [11C]-verapamil. Epilepsia 2012,53(Suppl. 6),60-63","journal-title":"Epilepsia"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1006\/mcbr.2001.0288","volume":"4","author":"Sukhai M.","year":"2000","unstructured":"Sukhai M.; Yong A.; Kalitsky J.; Piquette-Miller M.; Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the mdr1a and mdr1b genes. Mol Cell Biol Res Commun 2000,4(4),248-256","journal-title":"Mol Cell Biol Res Commun"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11060-012-0946-9","volume":"110","author":"Calatozzolo C.","year":"2012","unstructured":"Calatozzolo C.; Pollo B.; Botturi A.; Dinapoli L.; Carosi M.; Salmaggi A.; Maschio M.; Multidrug resistance proteins expression in glioma patients with epilepsy. J Neurooncol 2012,110(1),129-135","journal-title":"J Neurooncol"},{"journal-title":"Doctoral dissertation, Utrecht University","author":"Marchetti S.","key":"ref=37","unstructured":"Marchetti S.; Effect of selected ABC-drug transporters and anticancer drug disposition in vitro and in vivo Doctoral dissertation, Utrecht University"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/1568011013354705","volume":"1","author":"Krishna R.","year":"2001","unstructured":"Krishna R.; Mayer L.D.; Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. Curr Med Chem Anticancer Agents 2001,1(2),163-174","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1523\/JNEUROSCI.22-14-05833.2002","volume":"22","author":"Rizzi M.","year":"2002","unstructured":"Rizzi M.; Caccia S.; Guiso G.; Richichi C.; Gorter J.A.; Aronica E.; Aliprandi M.; Bagnati R.; Fanelli R.; D\u2019Incalci M.; Samanin R.; Vezzani A.; Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance. J Neurosci 2002,22(14),5833-5839","journal-title":"J Neurosci"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2125.2001.01359.x","volume":"51","author":"Owen A.","year":"2001","unstructured":"Owen A.; Pirmohamed M.; Tettey J.N.; Morgan P.; Chadwick D.; Park B.K.; Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001,51(4),345-349","journal-title":"Br J Clin Pharmacol"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuropharm.2016.06.007","volume":"109","author":"Bankstahl M.","year":"2016","unstructured":"Bankstahl M.; Klein S.; R\u00f6mermann K.; L\u00f6scher W.; Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice. Neuropharmacology 2016,109,183-195","journal-title":"Neuropharmacology"},{"key":"ref=42","first-page":"DTI","volume":"7","author":"Amin ML","year":"2013","unstructured":"Amin ML; P-glycoprotein inhibition for optimal drug delivery.  Drug target insights 2013,7,DTI-S12519","journal-title":"Drug target insights"},{"key":"ref=43","first-page":"728","volume":"17","author":"Deng X","year":"2018","unstructured":"Deng X; Xie Y; Chen Y; Effect of neuroinflammation on ABC transporters: possible contribution to refractory epilepsy. (CNS  2018,17(10),728-35","journal-title":"(CNS"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"137","DOI":"10.18773\/austprescr.2014.050","volume":"37","author":"Finch A.","year":"2014","unstructured":"Finch A.; Pillans P.; P-glycoprotein and its role in drug-drug interactions. Aust Prescr 2014,37(4),137-139","journal-title":"Aust Prescr"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1124\/mol.108.046680","volume":"73","author":"Robey R.W.","year":"2008","unstructured":"Robey R.W.; Lazarowski A.; Bates S.E.; P-glycoprotein--a clinical target in drug-refractory epilepsy? Mol Pharmacol 2008,73(5),1343-1346","journal-title":"Mol Pharmacol"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fneur.2017.00301","volume":"8","author":"Tang F.","year":"2017","unstructured":"Tang F.; Hartz A.M.S.; Bauer B.; Drug-resistant epilepsy: multiple hypotheses, few answers. Front Neurol 2017,8,301","journal-title":"Front Neurol"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.seizure.2017.07.014","volume":"51","author":"Kambli L.","year":"2017","unstructured":"Kambli L.; Bhatt L.K.; Oza M.; Prabhavalkar K.; Novel therapeutic targets for epilepsy intervention. Seizure 2017,51,27-34","journal-title":"Seizure"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"Kwan P.","year":"2000","unstructured":"Kwan P.; Brodie M.J.; Early identification of refractory epilepsy. N Engl J Med 2000,342(5),314-319","journal-title":"N Engl J Med"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00424-009-0772-x","volume":"460","author":"Zamponi G.W.","year":"2010","unstructured":"Zamponi G.W.; Lory P.; Perez-Reyes E.; Role of voltage-gated calcium channels in epilepsy. Pflugers Arch 2010,460(2),395-403","journal-title":"Pflugers Arch"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2010.02797.x","volume":"51","author":"Cain S.M.","year":"2010","unstructured":"Cain S.M.; Snutch T.P.; Voltage-gated calcium channels in epilepsy. Epilepsia 2010,51,11","journal-title":"Epilepsia"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neuron.2014.03.016","volume":"82","author":"Simms B.A.","year":"2014","unstructured":"Simms B.A.; Zamponi G.W.; Neuronal voltage-gated calcium channels: structure, function, and dysfunction. Neuron 2014,82(1),24-45","journal-title":"Neuron"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"a022723","DOI":"10.1101\/cshperspect.a022723","volume":"6","author":"Rajakulendran S.","year":"2016","unstructured":"Rajakulendran S.; Hanna M.G.; The role of calcium channels in epilepsy. Cold Spring Harb Perspect Med 2016,6(1),a022723","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/ijms19092735","volume":"19","author":"Xu J.H.","year":"2018","unstructured":"Xu J.H.; Tang F.R.; Voltage-dependent calcium channels, calcium binding proteins, and their interaction in the pathological process of epilepsy. Int J Mol Sci 2018,19(9),2735","journal-title":"Int J Mol Sci"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.eplepsyres.2003.12.009","volume":"58","author":"Volk H.A.","year":"2004","unstructured":"Volk H.A.; Potschka H.; L\u00f6scher W.; Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res 2004,58(1),67-79","journal-title":"Epilepsy Res"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1523\/JNEUROSCI.20-13-04829.2000","volume":"20","author":"Brumberg J.C.","year":"2000","unstructured":"Brumberg J.C.; Nowak L.G.; McCormick D.A.; Ionic mechanisms underlying repetitive high-frequency burst firing in supragranular cortical neurons. J Neurosci 2000,20(13),4829-4843","journal-title":"J Neurosci"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1528-1167.2005.59204.x","volume":"46","author":"Iannetti P.","year":"2005","unstructured":"Iannetti P.; Spalice A.; Parisi P.; Calcium-channel blocker verapamil administration in prolonged and refractory status epilepticus. Epilepsia 2005,46(6),967-969","journal-title":"Epilepsia"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.seizure.2013.09.009","volume":"23","author":"Nicita F.","year":"2014","unstructured":"Nicita F.; Spalice A.; Papetti L.; Nikanorova M.; Iannetti P.; Parisi P.; Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study. Seizure 2014,23(1),36-40","journal-title":"Seizure"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1124\/mol.107.041210","volume":"73","author":"Bauer B.","year":"2008","unstructured":"Bauer B.; Hartz A.M.; Pekcec A.; Toellner K.; Miller D.S.; Potschka H.; Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 2008,73(5),1444-1453","journal-title":"Mol Pharmacol"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.neuropharm.2009.09.012","volume":"58","author":"van Vliet E.A.","year":"2010","unstructured":"van Vliet E.A.; Zibell G.; Pekcec A.; Schlichtiger J.; Edelbroek P.M.; Holtman L.; Aronica E.; Gorter J.A.; Potschka H.; COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2010,58(2),404-412","journal-title":"Neuropharmacology"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.neuropharm.2009.01.009","volume":"56","author":"Zibell G.","year":"2009","unstructured":"Zibell G.; Unkr\u00fcer B.; Pekcec A.; Hartz A.M.; Bauer B.; Miller D.S.; Potschka H.; Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009,56(5),849-855","journal-title":"Neuropharmacology"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/mi.10.5.6","volume":"10","author":"Hartz A.M.","year":"2010","unstructured":"Hartz A.M.; Bauer B.; Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol Interv 2010,10(5),293-304","journal-title":"Mol Interv"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"13966","DOI":"10.1096\/fj.201901460RR","volume":"33","author":"Soldner E.L.B.","year":"2019","unstructured":"Soldner E.L.B.; Hartz A.M.S.; Akanuma S.I.; Pekcec A.; Doods H.; Kryscio R.J.; Hosoya K.I.; Bauer B.; Inhibition of human microsomal PGE2 synthase-1 reduces seizure-induced increases of P-glycoprotein expression and activity at the blood-brain barrier. FASEB J 2019,33(12),13966-13981","journal-title":"FASEB J"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1124\/jpet.109.152520","volume":"330","author":"Pekcec A.","year":"2009","unstructured":"Pekcec A.; Unkr\u00fcer B.; Schlichtiger J.; Soerensen J.; Hartz A.M.; Bauer B.; van Vliet E.A.; Gorter J.A.; Potschka H.; Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J Pharmacol Exp Ther 2009,330(3),939-947","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neures.2006.06.003","volume":"56","author":"Takemiya T.","year":"2006","unstructured":"Takemiya T.; Maehara M.; Matsumura K.; Yasuda S.; Sugiura H.; Yamagata K.; Prostaglandin E2 produced by late induced COX-2 stimulates hippocampal neuron loss after seizure in the CA3 region. Neurosci Res 2006,56(1),103-110","journal-title":"Neurosci Res"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.neuropharm.2008.02.008","volume":"54","author":"Bankstahl J.P.","year":"2008","unstructured":"Bankstahl J.P.; Hoffmann K.; Bethmann K.; L\u00f6scher W.; Glutamate is critically involved in seizure-induced overexpression of P-glycoprotein in the brain. Neuropharmacology 2008,54(6),1006-1016","journal-title":"Neuropharmacology"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/0973-7847.99898","volume":"6","author":"Kumar G.P.","year":"2012","unstructured":"Kumar G.P.; Khanum F.; Neuroprotective potential of phytochemicals. Pharmacogn Rev 2012,6(12),81-90","journal-title":"Pharmacogn Rev"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1046\/j.1528-1157.2001.33600.x","volume":"42","author":"Lim L.L.","year":"2001","unstructured":"Lim L.L.; Foldvary N.; Mascha E.; Lee J.; Acetazolamide in women with catamenial epilepsy. Epilepsia 2001,42(6),746-749","journal-title":"Epilepsia"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1177\/106002809603000515","volume":"30","author":"Reiss W.G.","year":"1996","unstructured":"Reiss W.G.; Oles K.S.; Acetazolamide in the treatment of seizures. Ann Pharmacother 1996,30(5),514-519","journal-title":"Ann Pharmacother"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3109\/00207454.2015.1015724","volume":"126","author":"Sun Y.","year":"2016","unstructured":"Sun Y.; Luo X.; Yang K.; Sun X.; Li X.; Zhang C.; Ma S.; Liu Y.; Yin J.; Neural overexpression of multidrug resistance-associated protein 1 and refractory epilepsy: a meta-analysis of nine studies. Int J Neurosci 2016,126(4),308-317","journal-title":"Int J Neurosci"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.12659\/MSM.903855","volume":"23","author":"Duan L.","year":"2017","unstructured":"Duan L.; Di Q.; Acetazolamide suppresses multi-drug resistance-related protein 1 and P-Glycoprotein expression by inhibiting aquaporins expression in a mesial temporal epilepsy rat model. Med Sci Monit 2017,23,5818-5825","journal-title":"Med Sci Monit"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/aps.2012.183","volume":"34","author":"Chen Y.H.","year":"2013","unstructured":"Chen Y.H.; Wang C.C.; Xiao X.; Wei L.; Xu G.; Multidrug resistance-associated protein 1 decreases the concentrations of antiepileptic drugs in cortical extracellular fluid in amygdale kindling rats. Acta Pharmacol Sin 2013,34(4),473-479","journal-title":"Acta Pharmacol Sin"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2174\/156802607780636690","volume":"7","author":"Supuran C.T.","year":"2007","unstructured":"Supuran C.T.; Carbonic anhydrases as drug targets--an overview. Curr Top Med Chem 2007,7(9),825-833","journal-title":"Curr Top Med Chem"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2174\/156802607780636726","volume":"7","author":"Thiry A.","year":"2007","unstructured":"Thiry A.; Dogn\u00e9 J.M.; Supuran C.T.; Masereel B.; Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem 2007,7(9),855-864","journal-title":"Curr Top Med Chem"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185051","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185051\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185051","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T09:28:05Z","timestamp":1638696485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185051\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,27]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,1,27]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527319999200819093109","relation":{},"ISSN":["1871-5273"],"issn-type":[{"type":"print","value":"1871-5273"}],"subject":[],"published":{"date-parts":[[2021,1,27]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}